Identifying & Creating the next generation of community-based cancer prevention studies: Summary of a national cancer institute think tank

Cancer Prevention Research

Volumn 10, Issue 2, 2017, Pages 99-107

  McCaskill Stevens, Worta ^a   Pearson, Deborah C ^a   Kramer, Barnett S ^a   Ford, Leslie G ^a   Lippman, Scott M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; NICOTINAMIDE; RALOXIFENE; TAMOXIFEN;

ADOLESCENT; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; CHILD; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DYSPLASTIC NEVUS; EARLY CANCER DIAGNOSIS; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSURVEILLANCE; MOUTH CANCER; NATIONAL HEALTH ORGANIZATION; OBESITY; PRECANCER; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; YOUNG ADULT; NEOPLASMS; PRIMARY PREVENTION; PROCEDURES;

HUMANS; NEOPLASMS; PRIMARY PREVENTION;

EID: 85011964944     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0230     Document Type: Review

References (31)

1. IOM (Institute of Medicine). A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
2. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: current status and future directions. CA Cancer J Clin 2015;65:345-83.
3. Kenzler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res 2016;9:2-10.
4. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The conundrum of genetic "drivers" in benign conditions. J Natl Cancer Inst 2016;108:pii:djw036.
5. Vogelstein B, Kinzler KW. The path to cancer -Three strikes and you're out. N Engl J Med 2015;373:1895-8.
6. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res 2014;7:487-95.
7. Beane JE, Campbell J, Moy C, Perdomo C, Schaffer M, Mazzilli S, et al. Abstract 2878: development of the pre-cancer genome atlas (PCGA) for squamous cell lung carcinoma. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18- 22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 2878.
8. Dunn GP, Bruce AT, Ikeda H, Old LJ, Scheiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
9. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
10. Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009;279:1-7.
11. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
12. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, Van Kamp GI, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
13. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
14. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
15. Keenan B, Jaffee EM. Immunotherapy in preneoplastic disease: Targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance. Ann N Y Acad Sci 2013; 1284:12-6.
16. Ai M, Curran M. Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother 2015;64: 885-92.
17. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proofof-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103: 1444-51.
18. Bibbins-Domingo K; US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836-45.
19. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, et al. 15- Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-73.
20. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23.
21. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-8.
22. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 2007;8:R201.
23. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015;373:243-51.
24. Perez-Rogers J, Gerrein J, Anderlind C, Liu G, Zhang S, Alekseyev Y, et al. Nasal epithelial gene expression is altered in patients with lung cancer and reflects the cancerassociated gene expression changes observed in the bronchial epithelium. Am J Respir Crit Care Med 2016;193:A7535.
25. Centers for Disease Control and Prevention. Vital signs: colorectal cancer screening test use - United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-8.
26. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262-6.
27. William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, et al. Erlotinib and the risk of oral cancer: The erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol 2016;2: 209-16.
28. Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013;5:199ra11.
29. Mascia F, Lam G, Keith C, Garber C, Steinberg SM, Kohn E, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013;5:199ra110.
30. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015;373:1618-26.
31. Thompson BC, Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol 2014;23:509-1.